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Background: Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is
associated with anti-tumor immunity suppression. It is highly expressed in many tumors, and its expression can be
regulated by the MAPK/MEK/ERK signaling pathway. The MAPK/MEK/ERK pathway has been reported to be a
regulator in tumor occurrence, development and clonal expansion. External-signal regulated kinase (ERK) is a vital
member of this pathway.
Results: The expression of DcR3 and ERK1/2 in tumor tissues of gastric cancer patients was significantly higher than
the non-cancerous group (P< 0.05). There was no statistical difference among tumor tissues from patients with
different ages or gender, and even of different differentiation (P> 0.05). However, in patients with stage I gastric
cancer, the DcR3 and ERK1/2 levels were significantly lower than patients with more advanced stages.
Conclusions: DcR3 and ERK1/2 play a vital role in the development of gastric cancer, and they may be new
markers for indicating the efficiency of gastric cancer treatment in the future.Background
Decoy receptor 3 (DcR3) is a member of the tumor necro-
sis factor receptor (TNFR) superfamily. It has been shown
to be the decoy receptor for Fas ligand (FasL), LIGHT and
TL1A [1-3], also known as TR6 [4]. DcR3 is mostly
expressed in tumor cells and competitively inhibits TNF
signaling. Overexpression of DcR3 in tumor cells protects
them from apoptosis. DcR3 protects tumor cells from im-
mune surveillance as it contributes to the suppression of
the host anti-tumor immunity.
DcR3 mRNA and protein are amplified in various malig-
nant tissues, such as lung cancer, colon cancer, gastric can-
cer, oesophageal carcinoma, pancreas cancer and malignant
melanoma [1,5,6]. Wu et al. [7] reported that DcR3 could
not be detected in non-tumor patients, but could be
detected in 98.8% (82/83) of patients with malignant
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reproduction in any medium, provided the orThis phenomenon demonstrates that the elevated DcR3
expression is significantly correlated with tumorigenesis
and tumor progression. Wu et al. [8] reported that DcR3
was highly expressed in human gastric cancer (GC), and
positively correlated with the development and metastases
of gastric lesions. Gastric cancer patients with a high DcR3
expression presented a more advanced pN2-3 disease than
those with a low DcR3 expression.
The DcR3 for FasL may be involved in the progression
of gastric cancer. Further evaluation of the possible roles
of DcR3 and the regulation of DcR3 expression in malig-
nant cells is very important for the development of new
strategies for controlling the growth of malignant cells that
escape the host immune surveillance.
At the early stage, the MAPK/ERK pathway is activated
in tumors, which is a notable sign for many kinds of cancers
in humans. Recently, several lines of evidence suggested
that ERK could be a parameter for predicting the prognosis
of various cancers such as breast cancer, colon cancer, pan-
creas cancer and cholangiocarcinoma. Wang et al. [9]
reported that the expression of ERK1/2 was high in cholan-
giocarcinoma, which correlated with the TNM stages.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The expression of DcR3 in gastric cancer and
non-cancerous tissues analyzed by RT-PCR (Figure 1a) and
Western blotting (Figure 1b). a: Lane M, DNA markers; lanes1-7,
tumor tissues; lane 8, non-cancerous tissues; DcR3 mRNA was positive
in 36 of 50 tumor tissues (1–7) and negative in non-cancerous tissues
(8). b: lanes1-7, tumor tissues; lane 8, non-cancerous tissues. DcR3
protein was positive in 37 of 50 samples of tumor tissue (1–7), which
only 3 of 50 in non-cancerous tissues (8).
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human intestinal epithelial cells (IEC), which appeared to
be via the activation of mitogen-activated protein kinases
(MAPK), such as extracellular signal-regulated kinase 1
and 2 (ERK1/2) and c-Jun NH2-terminal protein kinase
(JNK). LPS-induced DcR3 release in SW480 cells was
abolished by ERK1/2 and JNK inhibitors. Furthermore,
Yang et al. [11] reported that 3 g/ml DcR3 markedly
induced the phosphorylation of ERK and p38.
In accordance with these reports, we propose that DcR3
and ERK1/2 are closely related. The DcR3 genes closely
correlated with the occurrence and development of many
kinds of tumors. In this study we investigated the expres-
sion level and location of DcR3 and ERK1/2 in gastric
cancer patients of different ages, gender, stage and differ-
entiation, to explore the relationship between DcR3/
ERK1/2 and gastric cancer occurrence and development.




Tumors were from gastric cancer patients who were
undergone endoscopic biopsy or curative operations in
Zhongshan hospital affiliated with Xiamen university.
Tumor tissues from which DNA and protein were isolated
were from fresh specimen of resection surgery. All sam-
ples were obtained with patient consent and approval of
the Committee on Medical Ethics of Zhongshan Hospital
Xiamen University.
Mice
All the experiments were performed using 6–8 weeks
male nude mice purchased from Model Animal Research
Center of Medical College Xiamen University. All the ani-
mals were housed under specific pathogen free conditions
with constant access to water and chow. All experimental
procedures were carried out following the approval of the
Animal Care and Use Committee of Xiamen University.
Cell culture
The human gastric cancer cell line BGC823 was main-
tained in our laboratory, which was cultured in flasks
with Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), and 1%
penicillin-streptomycin at 37°C in an humidified atmos-
phere of 5% CO2.
Reagents
DMEM, FBS and penicillin-streptomycin were purchased
from Hyclone Corporation (Utah, USA). Hematoxylin-and-
eosin (H&E) assay kit were purchased from Chemicon
International, Inc (Temecula, CA, USA). ERK1/2 and DcR3
Abs were purchased from Santa Cruz Bio technology. RT-RCR reagents were purchased from TaKaRa (Dalian,
China). The primer sequence was synthesized from Sangon
(Shanghai, China).
In vivo animal tumor models
Tumors were generated in male nude mice by intramus-
cular (i.m.) injection of BGC823 cells (1.0 × 105 cells in
100μL PBS) into the right flank. Tumor measurements
were converted to tumor volume (V) by the formula (L ×
W2× 0.52), where L and W are the length and width,
respectively. Measurements were made with a vernier
caliper. All tumor-bearing mice were divided randomly
into groups (2 mice/group).
RT-PCR and Western blotting analysis for examining the
expression of DcR3/ERK
Total RNA of DcR3 and ERK1/2 was extracted from stimu-
lated cells using Trizol. To measure ERK/DcR3 gene copy
number, DNA from fresh tumor samples was analyzed with
RT-PCR. The upstream and downstream primers for ERK1
mRNA were 5'-CCTGCTCATCAACACCACC-3’ and
5'-CGTAGCCACATACTCCGTCA-3’, and for ERK2
mRNA were 5'-TCTTCC AGCCCTCCTTCCTG-3' and
5'-CGTTTCTGCGCCGTTAGGT-3'. The samples were
denatured at 95°C for 4 min, followed by 35 cycles of
amplification (95°C, 45 sec; 55°C, 45 sec; and 72°C,
60 sec). The products were 300-bp and 400-bp fragments
respectively. For DcR3 mRNA, the upstream primer was
5'- GCAAAGCCAAGGATTCCCCCTG -3’ and the down-
stream primer was 5'-GGCACTGCTCTGAGCTGGAG
CTG-3’. The samples were denatured at 95°C for 4 min,
followed by 30 cycles of amplification (95°C, 45 sec; 55°C,
45 sec; and 72°C, 60 sec). The product was a 921-bp
fragment.
Table 1 Analysis of gastric cancer patients with DcR3 and
ERK1/2 expression in tumor and normal tissues
Cases Positive number Positive rate (%)
Tumor 50 mRNA Protein +/+ mRNA Protein +/+
P< 0.05
DcR3 36 37 28 72.0 74.0 56.0
ERK1 37 42 36 74.0 84.0 72.0
ERK2 32 37 27 64.0 74.0 54.0
Non-cancerous 50
DcR3 2 3 0 4.0 6.0 0
ERK1 6 5 1 12.0 15.0 2.0
ERK2 9 10 3 18.0 20.0 6.0
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buffer (1% (v/v) Nonidet P-40, 150 mM NaCl, 50 mM
Tris–HCl (pH 8), 1 mM PMSF, 2 g/ml aprotinin, and
2 g/ml leupeptin) which could release DcR3 and ERK1/2
proteins. Twenty-five micrograms of total lysate was
fractionated by SDS-PAGE and subjected to Western
blotting analysis using the anti-ERK or anti-DcR3 mAb
(clone 3 H5).
Western blotting and ELISA assay for examining the
expression of DcR3/ERK after inhibitors treatment
BGC823 cells culture supernatants were collected at
various intervals, and levels of U0126, PD98059, APDC,
MEK1/2 and ERK1/2 interferences were quantified using
commercial ELISA kits, according to the vendor’s
instructions. Cells treated with ERK1/2 shRNA (5:2, 6:2),
U0126/PD98059 (0 μmol/L, 5 μmol/L, 10 μmol/L,
20 μmol/L, 40 μmol/L) and APDC (0 μmol/L, 10 μmol/
L, 20 μmol/L, 40 μmol/L, 80 μmol/L), respectively. After
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Figure 2 The expression of ERK1/2 in gastric cancer and non-cancero
(Figure 2b). a: Lane M, DNA markers; lanes1-7, tumor tissues; lane 8, non-c
b: ERK1 and ERK2 protein were positive in tumor tissues (1–8).cytokines as indicated assay. Twenty-five micrograms of
total lysate was fractionated by SDS-PAGE and subjected
to Western blotting analysis using the anti-ERK or anti-
DcR3 mAb (clone 3 H5).
Immunohistochemistry analysis for the expression of
DcR3 and ERK1/2
Tumor tissues were fixed in a formaldehyde medium and
embedded in paraffin. Sections 6 mm thick were mounted
on glass slides pretreated with 0.1% poly-L-Lysine. They
were then deparaffinaged in xy-lene, dehydrated in graded
ethanol and soaked in 3% H2O2 for 10 min to eliminate
endogenous peroxidase activity. Next, the slides were sub-
merged in citrate buffer (pH 6.0) and boiled at 92–98°C in
a microwave oven for 10 min. Subsequently, they were
rinsed 3 times with PBS for 10 min each and blocked with
10% normal goat serum in PBS for 1 hr at room
temperature. The slides were then reacted with the
affinity-purified rabbit anti-TR6 Ab (1.67 g/ml) at room
temperature for 2 hr. After washing, the slides were incu-
bated with biotinylated goat-anti-rabbit antibody for
10 min. TR6 signal was revealed by streptavidin-peroxidase
using DAB as a substrate according to instructions from
the Histostain-Plus kit (Zymed Laboratories, South San
Francisco, CA). DcR3 signals were revealed in brown.
Finally, the slides were counterstained with hematoxylin
and sealed with Aqueous Mounting Media (Zymed).
Statistical analysis
Data were presented as mean ± SD. The significance of
the difference between the groups was assessed by
Student`s two-tailed t-test. Probability value of less than
0.05 was considered significant. All means were calcu-
lated from at least three independent experiments.ERK1(44KD) 
ERK2(42KD) 
-actin 
6 7  8




us tissues analyzed by RT-PCR (Figure 2a) and Western blotting
ancerous tissues; ERK1 and ERK2 mRNA were positive in tumor tissues.
Figure 3 The location of ERK1/2 protein in gastric cancer tissues analyzed by immunohistochemistry. A: Control, B: ERK1, C: ERK2.
Table 2 Correlation of expression of DcR3 and ERK1/2
with age in gastric cancer patients
Cases Positive number Positive rate (%)
≥50 32 mRNA Protein +/+ mRNA Protein +/+
P> 0.05
DcR3 25 28 21 78.1 87.5 65.6
ERK1 28 31 26 87.5 96.9 81.2
ERK2 20 22 16 62.5 68.8 50.0
<50 18
DcR3 11 9 5 61.1 50.0 27.8
ERK1 13 11 5 72.2 61.1 27.8
ERK2 12 15 6 66.7 83.3 33.3
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Cancer patients have elevated DcR3 levels
To study the correlation between DcR3 expression and
tumor occurrence and development, tumors from 50
gastric cancer patients were collected and tested for
DcR3 mRNA and protein levels. As shown in Figure 1a,
the 921 bp DcR3 bands were generated by RT-PCR from
the tumor tissues of most patients (36/50), compared
with the non-cancerous tissues (2/50) from the same
organs of these patients. These results demonstrate that
DcR3 levels were significantly increased (eight randomly
picked clinical samples are shown in Figure 1a). To fur-
ther confirm our results, the DcR3 protein levels were
examined by western blotting. The results demonstrate
that DcR3 protein could be detected in most cancer
patients; DcR3 protein was detected in 74% (37/50) of
the tumor tissues, but only in 6% (3/50) of the non-
cancerous tissues (Table 1 and Figure 1b; eight randomly
picked clinical samples are shown in Figure 1b).
Expression of ERK1/2 in Clinical samples
To identify the signaling molecules related to DcR3, the
expression levels of ERK1/2, JNK and p38 were tested.
We found that only ERK1/2 could be detected in tumor
samples (data not shown for JNK and p38). ERK1
mRNA was detected in 74% of the samples (37/50), and
ERK2 mRNA was detected in 64% of the samples (32/
50; Table 1 and Figure 2a). At the protein level, ERK1
was detected in 84% (42/50) and ERK2 in 74% (37/50) of
the tumor tissues (Table 1 and Figure 2b). These results
indicate that patients with gastric cancer tumors have a
higher ERK1/2-positive occurrence compared with the
non-cancerous tissues (P< 0.05). There was a positive
correlation between the mRNA and protein levels, as in
42 of 50 tumor tissues the ERK1 protein level was ele-
vated, of which 36 cases were consistent with the mRNA
expression. In contrast, ERK1 protein expression was
detected only in five normal tissues. When examining
ERK2, 37 of 50 cases of tumor tissues were positive forERK2 protein expression, of which 27 cases were con-
sistent with the ERK2 mRNA expression, while only ten
cases showed positive protein expression in normal tis-
sues. The eight randomly picked samples are shown in
Figure 2.
Location of ERK1/2 in gastric cancer patients
To examine ERK1/2 distribution, tumors from 50
patients were tested by immunohistochemistry. The
results show that ERK1/2 were expressed in tumor tis-
sues from most of the patients. ERK1 expression was
found in the cytoplasm. ERK2 positive expression was
found in some tumor cells (Figure 3).
DcR3 and ERK1/2 levels correlate with tumor invasion but
not with age, gender or differentiation
The positive incidence of DcR3 mRNA in tumor tissues
of gastric cancer patients was 72.0% (36/50), and of
DcR3 protein 74.0% (37/50), which was significantly
higher than in non-cancerous tissues showing only 4%
(2/50) and 6% (3/50), respectively (P< 0.05; Table 1).
The positive occurrence of ERK1/2 mRNA expression
was 74.0% (37/50) and 64.0% (32/50), and of protein ex-
pression 84.0% (42/50) and 74.0% (37/50). Both of them
were significantly higher than the non-cancerous tissues,
Table 3 Correlation of expression of DcR3 and ERK1/2
with gender in gastric cancer patients
Cases Positive number Positive rate (%)
Male 39 mRNA Protein +/+ mRNA Protein +/+
P> 0.05
DcR3 29 29 24 74.4 74.4 61.5
ERK1 32 35 28 82.1 89.7 71.8
ERK2 26 30 23 66.7 76.9 59.0
Female 11
DcR3 7 8 5 63.6 72.7 45.6
ERK1 9 7 6 81.8 63.6 54.5
ERK2 6 7 4 54.6 63.6 36.4
Table 5 Correlation of expression of DcR3 and ERK1/2




Cases Positive number Positive rate (%)
I 6 mRNA Protein +/+ mRNA Protein +/+
P> 0.05
DcR3 1 1 1 16.7 16.7 16.7
ERK1 2 2 1 33.3 33.3 16.7
ERK2 1 1 0 16.7 16.7 0.0
II 17
P< 0.05
DcR3 12 13 10 70.6 76.5 58.8
ERK1 14 14 11 82.4 82.4 64.7
ERK2 10 12 9 58.8 70.6 52.9
III 25
P< 0.05
DcR3 21 21 21 84.0 84.0 84.0
ERK1 23 24 22 92.0 96.0 88.0
ERK2 20 23 18 80.0 92.0 72.0
IV 2
P< 0.05
DcR3 2 2 2 100.0 100.0 100.0
ERK1 2 2 2 100.0 100.0 100.0
ERK2 1 1 1 50.0 50.0 50.0
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and 20.0% (10/50), respectively (Table 1). These results
suggest that DcR3 and ERK1/2 expression levels correlated
with tumor occurrence and development.
As shown in Tables 2, 3 and 4, there was no significant
difference between tumor tissues from different ages, gen-
der groups and patients with different differentiation
stages of gastric cancer (P> 0.05). However, DcR3 and
ERK1/2 expression levels were significantly high in TNM
stage II-IV (Table 5). Thus, the expressions of DcR3 and
ERK1/2 correlated with tumor invasion and TNM stage,
but not with age, gender or differentiation.
Expression levels of DcR3 and ERK1/2 are amplified in
animal models
As shown in Table 6, after injecting BGC823 cells into
the right flank of nude mice, the tumors grew each day.
RT-PCR was used to test DcR3 and ERK1/2 mRNA
levels in the tumors and western blot analysis was used
to examine protein levels. In gastric cancer animal mod-
els, DcR3, ERK1 and ERK2 were detected at 921 bp,
300 bp and 400 bp, respectively. In these tumor tissuesTable 4 Correlation of expression of DcR3 and ERK1/2
with tumor differentiation in gastric cancer patients
Cases Positive number Positive rate (%)
Well 9 mRNA Protein +/+ mRNA Protein +/+
P> 0.05
DcR3 7 7 5 77.8 77.8 55.6
ERK1 7 9 6 77.8 100.0 66.7
ERK2 6 7 5 66.7 77.8 55.6
Moderately 28
DcR3 21 23 20 75.0 82.1 71.4
ERK1 24 24 22 85.7 85.7 78.6
ERK2 19 24 17 67.9 85.7 60.7
Low 13
DcR3 8 7 5 61.5 53.9 38.5
ERK1 10 9 8 76.9 69.2 61.5
ERK2 7 6 5 53.9 46.2 38.5DcR3 mRNA was detected from day six, peaked on day
10, and remained detected on day 12. DcR3 was also
detected from day six to day 12 in liver, while it was only
detected on day 12 in heart and lung (Figure 4a). ERK1/
2 mRNA expressions were detected from day four in
tumor tissues, and ERK1 mRNA peaked on day 10
(Figure 4a and Table 7).
DcR3 protein was detected on day six in tumor tissues
and liver, and the expression remained until day 12.
DcR3 protein was detected on day 10 in spleen and by
day 12 in heart, kidney and lung. ERK1 protein was
detected on day four in tumor tissues, and continued to
increase each day. ERK1 protein remained at a stable
level in heart, liver and kidney, but it decreased in lung
and spleen on day 10, after reaching the peak. ERK2 was
detected on day two in spleen and tumor tissues. From
day four, ERK2 protein was detected in all six samples,
and continued to increase till day 12. These results sug-
gest that ERK1 and ERK2 might have different effects on
tumor occurrence, development and clonal expansion.Table 6 Weight of BGC823 tumor in nude mouse (x ± s,
n = 6)
Group Δ weight/ mg
2 d 4d 6d 8d 10 d 12 d
Normal — — — — — —

















































Figure 4 The expression of DcR3 and ERK1/2 in mouse models analyzed by RT-PCR (Figure 4a) and Western blotting (Figure 4b). a:
Lane M, DNA marker; lanes1-6, hearts, livers, spleens, lungs, kidneys and tumor tissues of mouse models on the fourth day; lanes7-12, which on
the eighth day ; lanes13-18, on the twelfth day; ERK1 mRNA was positive in lane2,8,9,12,14,15,18, ERK2 mRNA was positive in
lane1,2,6,9,10,12,13,14,15,17,18. DcR3 mRNA was detected in lane8, 12, 13, 14, 15, 16, 17, 18. b: lane 1, heart; lane2, liver; lane3, spleen; lane4,lung;
lane5, kidney; lane6, tumor tissues; The expression of ERK1 protein increased in tumor tissues as time went on, in heart, liver and kidney persisted
for 12 days, The expression of ERK2 could be detected in spleen and tumor from the second day which was positive in tumor tissues till the
fourth day and all of five organs to the twelfth day. The expression of DcR3 protein was positive in tumor tissues and liver on the sixth day and
in spleen on the tenth day, which was negative in heart, lung, kidney until the twelfth day.
Table 7 Expression of DcR3 and ERK1/2 mRNA in tumor
tissues of animal models analyzed by RT-PCR
2d 4d 6d 8d 10d 12d
DcR3 — — + + ++ ++
ERK1 — + + + ++ ++
ERK2 — + + + + +
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http://www.biomedcentral.com/1471-2172/13/28DcR3 expression decreased after inhibiting the expression
or phosphorylation of ERK1/2 in BGC823 cells
To investigate the effect of ERK1/2 expression and phos-
phorylation on DcR3 expression, BGC823 cells were treated
with ERK1/2 shRNA or with inhibitors that specifically
regulate the ERK pathway. Western blot analysis confirmed
that the inhibitors efficiently blocked the phosphorylation
of the MEK/ERK pathway molecules, and that the shRNA
significantly reduced the expression of ERK1/2 (Figure 5).
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http://www.biomedcentral.com/1471-2172/13/28As shown in Figure 5A, when BGC823 cells were treated
with ERK1/2 shRNA, ERK1/2 and P-ERK1/2 levels
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Figure 5 The expression of ERK1/2 and P-ERK1/2 in BGC823 cell
line with plasmid interference and inhibitor detected by
Western blotting. a: The expression levels of ERK1/2 and P-ERK1/2
declined compared with the control. 1) control group; 2) 5:2 (plasmid:
reagent); 3) 6:2 (plasmid: reagent). b: ERK1/2 phosphorylation gradually
declined as the concentrations of the inhibitor U0126, PD98059
increased, but total ERK1/2 protein expression hardly changed. 1)
0 μmol/L; 2) 5 μmol/L; 3) 10 μmol/L; 4) 20 μmol/L; 5) 40 μmol/L. c: ERK1/
2 phosphorylation gradually declined as the concentrations of the
inhibitor APDC. 1) 0 μmol/L; 2) 10 μmol/L; 3) 20 μmol/L; 4) 40 μmol/L; 5)
80 μmol/L. d: PD98059 can obviously inhibit the MEK1/2
phosphorylation level, but it did not alter MEK1/2 or NF-κB expression
levels. 1) 0 μmol/L; 2) 5 μmol/L; 3) 10 μmol/L; 4) 20 μmol/L; 5) 40 μmol/L.U0126 is a very effective MEK inhibitor, resulting in the
inhibition of ERK phosphorylation, as does PD98059. ERK
phosphorylation gradually declined as the concentrations
of the drugs increased, although total ERK1/2 protein ex-
pression hardly changed (Figure 5B).
APDC can inhibit NF-κB cell activation in a variety of
cells. Through the degradation of IκB, APDC can decrease
the translocation of NF-κB, thus blocking NF-κB activation.
As shown in Figure 5 C, under different concentrations of
APDC, changing the level of NF-κB inhibition can signifi-
cantly attenuate ERK1/2 phosphorylation levels. However,
the specific mechanism requires further investigation.
To examine the effect of these inhibitors and shRNA
on DcR3 expression we used ELISA analysis, which
demonstrated that secreted DcR3 in the supernatant
decreased after the different treatments (Figure 6). Statis-
tical analysis showed that DcR3 secretion levels were sig-
nificantly different between the experiment groups and
control groups (P< 0.05). As shown in Figure 6, interfer-
ence with ERK1/2 in BGC823 cells led to decreased DcR3
protein expression compared with the control group. The
trend matches the ERK expression level in Figure 5 and
proves that the two are positively correlated. Further-
more, DcR3 and P-ERK expression levels decreased when
cells were treated with different concentrations of U0126,
PD98059 and APDC. This data indicates that secretion of
DcR3 positively correlated with P-ERK1/2 expression
levels in BGC823 gastric cells. It is worth noting that in
the U0126 group, DcR3 secretion levels increased when
the drug concentration reached 40 μmol/L; however, the
specific mechanism requires further investigation. In the
APDC group, DcR3 levels did not change significantly at
concentrations higher than 20 μmol/L.
Discussion
It has been demonstrated that the DcR3 gene is
expressed at a low level in human embryo, lung, brain,
liver, spleen, stomach, colon, lymph nodes and spinal
cord, whereas it was expressed at a high level in cancers
such as gastrointestinal cancer, hepatocellular carcinoma
and pancreatic cancer [1,12].
Wu et al. [8] reported that the expression of DcR3
in gastric cancer patients was significantly higher than
normal. DcR3 expression in the well-differentiated
gastric cancer was significantly lower than that of
poorly differentiated specimens (P< 0.05).
The DcR3 expression level was significantly associated
with lymph node metastasis and pathological stage, but
did not correlate with tumor size, metastatic status, or
histological types. When patients were followed-up for
63 months, DcR3 overexpression was found to be asso-
ciated with a significantly shortened survival rate [13,14].
Many reports have shown that high expression levels
















































































































































































Figure 6 The expression of DcR3 protein with plasmid interference and inhibitor by ELISA analysis. a: DcR3 expression levels in BGC823
culture supernate decreased when cells were treated with ERK1 interference plasmid. b: DcR3 expression levels decreased when cells were treated with
ERK2 interference plasmid. c: DcR3 expression levels decreased when cells were treated with different concentrations of U0126, PD98059 and APDC μmol/L.
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http://www.biomedcentral.com/1471-2172/13/28pancreatic cancer, as well as malignant melanoma,
leukemia and myxoma [15-18].
Our research showed that in patients with gastric can-
cer, the positive incidence of DcR3 and ERK1/2 mRNAwas higher than that in the non-cancerous tissues
(P< 0.05). RT-PCR and western blotting showed that
the mRNA and protein expression levels of DcR3 and
ERK1/2 in tumor tissues were significantly higher than
Yang et al. BMC Immunology 2012, 13:28 Page 9 of 10
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ERK1/2 levels correlate with tumor development but not
with age, gender or differentiation (P> 0.05).
Our results showed that the positive incidence of ex-
pression of DcR3 and ERK1/2 mRNA and DcR3 and
ERK1/2 protein matched each other. The immunohisto-
chemistry results also demonstrated that in gastric
tumors, ERK1/2 was highly expressed.
Chen et al. [19] reported that the positive rate of
DcR3 expression was 74.4% (32/43) in hepatocellular
carcinoma, and that there was a significant correlation
between DcR3 expression and metastasis as well as
recurrence and differentiation.
In the mouse gastric model, RT-PCR showed that
DcR3 mRNA could be detected in tumors from day six.
ERK1/2 mRNA and protein were also detected in
tumors, and ERK1 levels gradually increased in gastric
tumors. Furthermore, they were also detected in heart,
liver, spleen, lung and kidney of the gastric cancer ani-
mal model, suggesting that they have an important role
in tumor progression. ERK1/2 mRNA was detected from
day four in tumor tissues, and ERK1 mRNA peaked on
day 10. ERK1 protein could also be detected on day four
in tumor tissues, and continued to increase every day.
ERK1 remained at a stable level in heart, liver and kid-
ney, but it decreased in lung and spleen on day 10, after
reaching the peak. ERK2 was detected on day two in
spleen and tumor tissues. From day four, ERK2 was
detected in all six tissues, and continued to increase till
day 12. ERK2 could not be detected in heart, lung and
spleen by RT-PCR on day 12 in animal models, but pro-
tein levels could be detected. These results suggest that
ERK1 and ERK2 might have different effects on tumor
occurrence, development and clonal expansion. Many
studies indicated that the expression of ERK1/2 mRNA
and protein varies in different tumors and cells [20,21].
Some recent reports suggested they could be entirely op-
posite in some cases. Thus, the effects of ERK1 and
ERK2 on the tumors are unlikely to be the same.
Conclusions
In conclusion, high expression of DcR3 and ERK1/2 may
suppress tumor cell apoptosis and play an influential
role in gastric cancer occurrence and development,
which is an important mechanism in tumorigenesis [22].
In our study, DcR3 and ERK1/2 presented an overex-
pression tendency, and participated in the tumor im-
munity. We infer that in the tumor occurrence and
developing process, the expression of ERK1/2 and DcR3
may be related to each other. Understanding the role of
ERK1/2 in DcR3 expression might shed light on gastric
cancer's diagnosis and identify a factor that regulates the
expression of DcR3. It might be a new marker for early
diagnosis of gastric cancer. DcR3 is a secreted protein,which can be detected in blood serum. Thus it could
serve as a reliable index for clinical malignant tumor
diagnosis, treatment and prognosis. Therefore, DcR3 has
the potential of becoming a novel tumor marker in the
future.
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